Skip to search formSkip to main contentSkip to account menu

BCX4208

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ulodesine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
FRI0380 Long-term safety of BCX4208 added to allopurinol in the chronic management of GOUT: Results of a phase 2 24-week blinded safety extension and vaccine challenge study
Background Most gout patients treated with 300 mg/d allopurinol do not reach the therapeutic goal range serum uric acid… 
2013
2013
FRI0367 BCX4208 added to allopurinol increases response rates in patients with GOUT who fail to reach goal range serum uric acid on allopurinol alone: A randomized, double-blind, placebo-controlled…
Background BCX4208, a novel purine nucleoside phosphorylase inhibitor, blocks uric acid production at a step preceding xanthine… 
2013
2013
FRI0401 BCX4208, a novel enzyme inhibitor for chronic management of GOUT, shows a low risk of potential drug-drug interactions
Background Common comorbidities associated with gout, including obesity, hypertension, diabetes, and chronic kidney disease, may… 
2013
2013
OP0106 Effect of BCX4208 add-on therapy to allopurinol 300 mg on plasma hypoxanthine and xanthine concentrations in gout patients
Background BCX4208 is an oral, once-daily, purine nucleoside phosphorylase (PNP) inhibitor in clinical development as add-on… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)